Overexpression of ErbB2 is frequent in cancer and understanding the mechanisms which regulate its expression is important. ErbB2 is considered endocytosis resistant. It has no identified ligand, but upon heterodimerization it is a potent mediator of proliferative signaling. A recent study established a role for protein kinase C (PKC) in internalization and recycling of ErbB2. We have now further investigated the molecular mechanisms involved in PKC-mediated downregulation of ErbB2. We confirm that PMA-induced PKC activation causes ErbB2 internalization, but while the Hsp90 inhibitor 17-AAG induced ErbB2 degradation, PMA had no such effect. When combined with 17-AAG, PMA had additive effect on ErbB2 internalization indicating that Hsp90 inhibition and PKC activation induce internalization by alternative mechanisms. We confirm that while 17-AAG-induced internalization was clathrin-mediated, PMA-induced internalization was clathrin independent. This difference may be explained by while both 17-AAG and PMA reduced the constitutive tyrosine phosphorylation of ErbB2, only 17-AAG induced Hsp90 dissociation, Hsp70 recruitment and ubiquitination of ErbB2. Importantly, since PMA induced internalization of ErbB2, but not dissociation of Hsp90, Hsp90 does not per se retain ErbB2 at the plasma membrane. The morphology of the compartment into which receptors are sorted upon PKC activation has not previously been identified. By immuno-electron microscopy, we show that PMA sorts ErbB2 into a complex tubulovesicular or cisternal organelle resembling a previously described endocytic recycling compartment.
studies have shown that the ErbB2-Hsp90 complex interacts with plasma membrane localized proteins such as the flotillins [38] , members of the ERM protein family [2] , the plasma membrane calcium ATPase2 (PMCA2) [21, 22] , and the scaffolding sodium-hydrogen exchanger regulatory factor 1 (NHERF1) [23] . Inhibition of these interactions can cause Hsp90 dissociation, c-Cbl mediated ubiquitination and internalization of ErbB2 [2, 21, 23, 38] . However, since ErbB2 mutants that do not bind Hsp90 are stable [49, 54] , it is unlikely that the retention directly depends on Hsp90. Likewise, it has been reported that Hsp90 dissociates from ErbB2 upon heterodimerization [9] , but ErbB2 still prevents internalization of EGFR-ErbB2 and ErbB2-ErbB3 heterodimers [16, 19, 42] . It has thus been suggested that inhibited downregulation of ErbB2 is due to an Hsp90-independent retention, but that Hsp90 inhibitors induce ErbB2 ubiquitination, which serves as a signal for internalization and degradation [7] .
The plasma membrane expression of ErbB2 can also be regulated by members of the protein kinase C (PKC) family [4, 34] . The PKCs are serine-and/or threonine kinases involved in numerous cellular processes and various human diseases (reviewed in [33] ). The family consists of conventional (classical) PKCs which require diacylglycerol (DAG), calcium ions (Ca 2+ ) and phospholipids for activation, novel
PKCs which need DAG, but not Ca 2+ , and atypical PKCs which require neither DAG, nor Ca 2+ but phosphatidylserine for full activation. The tumor promoting phorbol ester, phorbol 12-myristate 13-acetate (PMA, also known as TPA), can mimic DAG and is a potent activator of conventional and novel PKCs. Several previous studies have shown that PKCs can regulate expression and localization of the EGFR. Upon PKC activation, EGFR gets phosphorylated on threonine 654 (Thr-654) and downregulated from the plasma membrane. Instead of being routed to lysosomes for degradation, it is sequestered in a modified endosomal compartment [5, 29, 30] . As for Thr-654 in EGFR, phorbol ester-induced activation of PKCs induces phosphorylation of Thr-686 in ErbB2 [34] , and while PKC inhibitors were found to reduce 17-AAG-induced downregulation of ErbB2, PKC activation caused downregulation of ErbB2 from the plasma membrane. Contrary to 17-AAG, activation of PKC did not induce ErbB2 degradation. Instead of being degraded, ErbB2 was stabilized in specialized endosomes [4] . Although PKC inhibitors were found to reduce the effect of 17-AAG, the effect of PKCs on ErbB2-Hsp90 interaction has, to our knowledge, not been investigated. Neither has it been shown whether PKCs have effects on ErbB2 ubiquitination. Internalization of plasma membrane constituents can occur by several different pathways. GA-induced internalization of ErbB2 has been shown to depend on clathrin-mediated internalization [36] . EGFinduced internalization of EGFR may, however, depending on EGF concentration and ubiquitination status, be both clathrin-dependent and -independent [11, 44] . Little is known about how receptors are internalized upon PKC activation. PKC-induced sequestration of certain plasma membrane molecules was reported to depend on clathrinmediated endocytosis. However, also molecules internalized by clathrin-independent internalization got sequestered [20] , but the inhibitors used, hypertonic sucrose or potassium depletion, are probably not specific [50] . The internalization pathway(s) thus remain(s) to be identified. Relatively little is known about the compartment into which the receptors are sequestered. The compartment is often referred to as the pericentrion, and based on being positive for, among others, Rab 11, it most likely represents a specialized endocytic recycling compartment (ERC) (reviewed in [1] ). In line with this, Bailey et al. showed that ErbB2 was sequestered in an Arf6 positive compartment upon PKC activation [4] . Several studies indicate that the PKCs regulate the dynamics and localization of signal transduction (reviewed in [41] ), and the data of Bailey et al. suggest that the pericentrion serves as a hub for ErbB2-mediated signaling [4] . However, nothing is to our knowledge known about the morphology of the pericentrion. Upon GA-induced internalization, ErbB2 is translocated to internal vesicles of multivesicular bodies (MVBs) [36] from which signaling is highly unlikely.
Morphological studies and localization of proteins within the pericentrion are thus important.
We have now further investigated how PKC activators and inhibitors affect ErbB2. In line with previous studies, we find that PMAinduced activation of PKC downregulates ErbB2 from the plasma membrane without causing ErbB2 degradation. We find that PKC activation has no effect on ErbB2-Hsp90 interaction, demonstrating that Hsp90 does not per se retain ErbB2 at the plasma membrane. PKC activation did not induce ubiquitination of ErbB2 and contrary to 17-AAG, PMA induced clathrin-independent internalization of ErbB2. Depletion of cholesterol did, however, inhibit the internalization suggesting a role of lipid rafts in PKC-regulated trafficking of ErbB2. Furthermore, we morphologically characterized the compartment into which ErbB2 is sequestered. Immuno-electron microscopy (immuno-EM) showed that ErbB2 was concentrated in a complex tubulovesicular or cisternal compartment resembling previously described ERCs.
Materials and methods

Reagents and antibodies
Mouse anti-ErbB2 extracellular domain (TAB250), rabbit anti-ErbB2 intracellular domain (PAD:Z4881), Alexa Fluor 555-conjugated donkey anti-mouse IgG and Alexa Fluor 647-conjugated donkey anti-goat IgG antibodies were from Thermo Fisher Scientific (Waltham, MA, USA). Mouse anti-ubiquitin, mouse anti-phosphotyrosine, rabbit anti-Hsp90, mouse anti-Hsp70 and goat anti-early endosome antigen 1 (EEA1) (N-19) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit anti-ErbB2 (29D8) was from Cell Signaling Technology (Danvers, MA, USA). Herceptin (trastuzumab) was from Roche Pharma (Grenzach-Wyhlen, Germany). Rabbit anti-β-tubulin, rabbit anti-LAMP1 and rabbit anti-PKCα antibodies were from Abcam (Cambridge, UK). Mouse-anti ErbB2 (42) and mouse anti-PKCδ antibodies were from BD Biosciences (San Jose, CA, USA). Alexa488-conjugated mouse antiErbB2 (24D2) antibody was from BioLegend (San Diego, CA, USA). Peroxidase-conjugated donkey anti-rabbit and anti-mouse IgG, as well as Alexa Fluor 488-conjugated donkey anti-human and anti-rabbit IgG antibodies were from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Rabbit anti-mouse IgG antibody was from Cappel Research Reagents (ICN Biochemicals, Irvin, CA). Ro 31-8220 was from Merck Millipore (Darmstadt, Germany). 17-AAG was from TOCRIS (Bio-Techne, Abingdon, UK). Unless specifically noted, all other materials and chemicals were from Sigma-Aldrich (St. Louis, MO, USA).
Cell culture and treatment
SK-BR-3 cells were grown in DMEM with Ultraglutamine I and 4.5 g/l Glucose (Lonza, Basel, Switzerland). A mixture of 50 units of Potassium Penicillin and 50 μg of Streptomycin Sulfate per 1 ml of DMEM and 15% (v/v) fetal bovine serum were routinely used. PAE.ErbB2 cells [35] were grown in Ham's F12 (Lonza) with 10% (v/v) fetal bovine serum, a mixture of 50 units of Potassium Penicillin and 50 μg of Streptomycin Sulfate, as well as 30 µg Zeocin (Thermo Fisher Scientific) per 1 ml of Ham's F12. 17-AAG, PMA and Ro 31-8220 were dissolved in DMSO and therefore DMSO was used as vehicle control in all experiments where PMA, 17-AAG or Ro 31-8220 was present.
siRNA transfection of cells
For knock-down experiments, cells were reversely transfected with short interfering RNA (siRNA) twice with a 48 h interval using Lipofectamine® RNAiMax (Thermo Fisher Scientific). Cells were used for experiments 48 h after the second transfection. The transfection was performed according to the manufacturer's protocol using a final concentration of 50 nM siRNA. For knock-down of clathrin heavy chain, the siRNA duplex to the target sequence GCAAUGAGCUGUUUGAAGA [18] was synthesized and annealed by Thermo Fisher Scientific. On-TARGETplus Non-targeting siRNA #2 (D-001810-02) was from Dharmacon (Horizon Discovery, Cambridge, UK).
Immunoblotting
Cells were lysed in SDS (sodium-dodecyl sulfate) lysis buffer [47] containing 10 μg/ml 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF). Lysates were subjected to homogenization using a QIAshredder column (QIAGEN, Valencia, CA, USA). Sample buffer [47] was added to the lysates before incubation for 10 min at 95°C. Proteins were separated by SDS-gel electrophoresis using 10% Mini-PRO-TEAN® TGXTM Precast Gels from Bio-Rad Laboratories (Hercules, CA, USA). Afterwards, proteins were blotted onto a nitrocellulose membrane using Trans-Blot® TurboTM Transfer System (Bio-Rad Laboratories). The membranes were incubated with 5% Blotting-Grade Blocker (Bio-Rad Laboratories) in TBS-Tween 20 before incubation with primary and secondary antibodies diluted in 1% Blotting-Grade Blocker in TBS-Tween 20 for 2 h at room temperature or over night at 4°C. For detection of proteins, Super Signal West Dura Extended Duration Substrate from Thermo Fisher Scientific was used. Visualization was achieved with the ChemiDoc MP System (Bio-Rad Laboratories). Image Lab Software version 4.0.1 build 6 (Bio-Rad Laboratories) and Adobe Photoshop (Adobe Systems, San José, CA, USA) were used for image processing.
Immunoprecipitation and co-immunoprecipitation
To study ubiquitination and phosphorylation of ErbB2, cells were lysed in preheated (100°C) 1% SDS in PBS, incubated at 100°C for 5 min and homogenized using a QIA-shredder column (QIAGEN). The lysates were added to protein A-coupled magnetic beads (2.8 µM) (Thermo Fisher Scientific) precoupled to rabbit anti-ErbB2 (PAD:Z4881) antibody in 0.1 M phosphate buffer, pH = 8, with 0.05% Triton X-100 at room temperature for 1 h. The beads were resuspended in 2x immunoprecipitation (IP) buffer (2% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, 1% (w/v) bovine serum albumin, 2 mM EDTA, 40 mM NaF, 6 mM NEM, 1:100 (v/v) protease inhibitor and phosphatase inhibitor cocktails (P8340 and P5726)). Antibody-coupled magnetic beads and cell lysates were gently mixed for 1 h at 4°C. The beads were then washed four times with 1x IP buffer (50% 2x IP buffer + 50% SDS [1%] in PBS), once in 1:10 diluted PBS and then eluted in 2x sample buffer (20 mM Tris-HCl pH 6.8, 10 mM EDTA, 100 mM NaF, 60 mM sodium pyrophosphate, 4% SDS, 2% β-Mercaptoethanol, 20% Glycerol, 0.006% Bromophenol Blue) at 95°C for 5 min. Immunoprecipitated ErbB2 was analyzed by immunoblotting with antibodies to ErbB2, phosphotyrosine and ubiquitin.
For co-immunoprecipitation analysis, cells were washed three times in ice-cold PBS and lysed for 30 min on ice in lysis buffer (20 mM HEPES pH 7.2, 0.1% Triton X-100, 2 mM MgCl2, 100 mM NaCl and 0.1 mM EDTA, supplemented with 1:100 protease and phosphatase inhibitor cocktails (P8340 and P5726), 60 mM Octyl β-D-glucopyranoside and 20 mM NEM (N-Ethylmaleimide)). The protein G-coupled magnetic beads (2.8 µM) (Thermo Fisher Scientific) were precoupled to rabbit anti-ErbB2 antibody. Preparation of the beads and all the washing steps were done as described above. Proteins were eluted from the beads in 2x sample buffer. For detection of co-immunoprecipitation eluted samples were blotted with antibodies to ErbB2, Hsp70 and Hsp90.
Flow cytometry
Cells were seeded one day prior to experiments in 6-well plates. Following treatment, cells were rinsed 3x with PBS and detached with trypsin/EDTA. Trypsinization was stopped by addition of trypsin inhibitor. Cell suspensions were transferred to 96-well plates and washed 2x with PBS. Cells were stained 30 min on ice with Fixable Viability Dye eFluor 450 (eBioscience, San Diego, CA, USA) for dead-live discrimination and afterwards washed 2x with FACS buffer (0.5% fetal bovine serum/0.1% EDTA pH = 8 in PBS). Cells were fixed at room temperature in 4% PFA for 10 min. For staining of plasma membrane localized ErbB2, cells were incubated for 30 min on ice with Alexa488-conjugated anti-ErbB2 antibody and washed 2x with FACS buffer. Stained cells were run using a LSR II flow cytometer from BD Biosciences (San Jose, CA, USA). Results were analyzed with FlowJo software version 10.1 (FlowJo, Ashland, OR, USA) and graphically displayed with GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA).
ErbB2 internalization assay and staining of cells
To verify ErbB2 internalization, cells were incubated with the humanized monoclonal anti-ErbB2 antibody Herceptin in MEM with 0.1% bovine serum albumin (BSA) for 30 min on ice. The cells were then chased in Herceptin-free medium (MEM+0.1% BSA) for 4 h at 37°C before fixation in 4% PFA for 10 min. After quenching with 50 mM NH 4 Cl and permeabilization with 0.01% Triton X-100, internalized Herceptin was detected using an Alexa Fluor 488-conjugated antihuman IgG antibody. To localize ErbB2, fixed and permeabilized cells were stained with an anti-ErbB2 extracellular domain (TAB250) antibody, followed by an Alexa Fluor 555-conjugated anti-mouse IgG antibody. EEA1 antibodies were detected with an Alexa Fluor 647-conjugated anti-goat antibody and LAMP1 antibodies were detected with an Alexa Fluor 488-conjugated anti-rabbit antibody.
Imaging and image analysis
Laser scanning confocal microscopy was done on an Olympus Fluoview 1000 (BX61W1) system with 405, 488, 543 and 633 nm laser lines and an UPlanSApo 60x oil objective with a numerical aperture of 1.35 (Olympus, Hamburg, Germany). Images were acquired with the FV10-ASW-v.42 software and montages were assembled in ImageJ (Version2.0.0-rc41/1.50d; Java 1.6.0_24 [64-bit]) from National Institutes of Health, USA.
Immuno-electron microscopy
Cells were fixed with 4% methanol-free paraformaldehyde and 0.1% glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA) in 0.2 M HEPES and prepared for cryo immuno-electron microscopy basically as described in [15] . Labeling for ErbB2 was done using mouse anti-ErbB2 (TAB250) followed by rabbit anti-mouse IgG. Bound antibodies were visualized using colloidal gold coated with protein A (G. Posthuma, Utrecht, The Netherlands). Sections were examined using a Tecnai G 2 Spirit TEM (FEI, Eindhoven, The Netherlands) equipped with a Morada digital camera using iTEM (SIS) software (Olympus Soft Imaging Solutions, Münster, Germany). Images were processed using Adobe Photoshop. To quantify labeling the total number of intracellular gold particles on a minimum of 25 cell profiles was counted and grouped with respect to organelle localization. For each condition, three parallel labeling experiments were included and the results are presented as mean ± SD. Non-specific labeling, as judged by labeling on mitochondria, was not included in the presented results, but when counted it was found to be minimal (about 1% of total labeling).
Statistical data analysis
Statistical analysis was performed using GraphPad Prism 6. Data analyzed were the results of at least three independent experiments. Mean ± SD was calculated and statistical significance was determined by using one unpaired t-test per row. Significance is denoted as n.s., non-significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Results and discussion
Both 17-AAG and PMA downregulate ErbB2 from the plasma membrane, but only 17-AAG induces ErbB2 degradation
It has previously been shown that both Hsp90 inhibition and PKC activation independently downregulate ErbB2 from the plasma membrane. To further investigate this, cells were pre-incubated with cycloheximide (CHX) to inhibit protein synthesis and ensure that the induced effects are not counteracted by upregulated protein synthesis. Flow cytometry confirmed the reported downregulation and we could furthermore identify an additive effect when 17-AAG and PMA were combined (Fig. 1A) . A previous study also identified an increased downregulation when PMA and 17-AAG were combined [4] , but the effect was then not directly additive. A likely explanation for the difference is the use of different concentrations of 17-AAG (25 nM vs. 3 µM). Since we used a 17-AAG concentration that can be expected to have maximal effect [4] , the added effect of PMA suggests that different mechanisms drive 17-AAG-and PMA-induced downregulation of ErbB2.
We also investigated the effects of 17-AAG and PMA on degradation of ErbB2. The samples were analyzed by immunoblotting for both the intracellular and the extracellular domain of ErbB2. This was done since Hsp90 inhibition has been reported to induce internalization of both full-length ErbB2 [28, 36] , and intracellularly cleaved ErbB2 [27, 48] . As shown in Fig. 1B -D, 17-AAG, but not PMA, induced a measurable degradation of ErbB2. Quantification showed similar effects when blotting for the extracellular and intracellular domain. When examining the gel, no low molecular weight bands, representing ErbB2 cleavage, were observed (data not shown). This supports our previous studies which concluded that ErbB2 was internalized and degraded as a full length receptor. Although treatment with PMA alone did not induce ErbB2 degradation, the combinatorial treatment again showed an increased effect and caused the strongest degradation. This could be due to the increased internalization of ErbB2 when 17-AAG and PMA were combined and, as discussed below, effects of 17-AAG on ubiquitination and degradation of ErbB2. Blotting for PKCα, a classical PKC, and PKCδ, a novel PKC, were included to confirm PMA-induced PKC activation and subsequent degradation (see Fig. 1B ).
PKC inhibition reverses effects of PMA, but not of 17-AAG
Based on the observed effects of PMA and/or 17-AAG we next tested how PKC inhibition affected ErbB2 expression. As especially PKCα has been implicated in the regulation of EGFR [52] , and SK-BR-3 cells have very low levels of PKCβ and PKCγ [26] , we used the PKC inhibitor Ro 31-8220 which mainly inhibits classical PKCs. While the PKC inhibitor alone did not show any significant effect on plasma membrane expression of ErbB2, it clearly reversed the PMA-induced downregulation of ErbB2 (Fig. 2A) . It has previously been reported that Ro 31-8220 also mildly inhibits the effect of 17-AAG [4] . However, we did not observe any inhibitory effect of Ro 31-8220 on 17-AAG-induced downregulation of ErbB2. As discussed above, this is probably due to the use of different 17-AAG concentrations.
When examining the degradation of ErbB2 there were no obvious effects of Ro 31-8220 alone or in combination with PMA ( Fig. 2B-C) . Nor did Ro 31-8220 have effect on 17-AAG-induced ErbB2 degradation (data not shown). This shows that PKC inhibition effectively inhibits PMA-induced ErbB2 downregulation, supporting that PKCs can regulate internalization of ErbB2. Furthermore, it also shows that 17-AAG-induced internalization and degradation is, at least at high 17-AAG concentrations, not dependent on a basal PKC activity. 
ErbB2 is internalized to complex tubulovesicular compartments upon PKC activation
To verify that PKC activation caused internalization of ErbB2, and determine its intracellular localization and sorting, we initially carried out an antibody-based internalization assay. Cells were incubated with the anti-ErbB2 antibody Herceptin on ice for 30 min, before wash and chase for 4 h at 37°C. It is discussed whether Herceptin alone can induce internalization of ErbB2, but in line with previous studies [17, 31] , we found no internalization of Herceptin in cells treated with DMSO only. Internalization could, however, clearly be seen in cells treated with 17-AAG, and although to a lesser extent, also in PMA-treated cells (Fig. 3) . After 17-AAG treatment, internalized Herceptin was found in both early endosome antigen 1 (EEA1) (Fig. 3A) and lysosomal-associated membrane protein 1 (LAMP1) (Fig. 3B) positive compartments. Upon incubation with PMA, Herceptin was found in compartments which were partially positive for EEA1, but negative for LAMP1. It has been previously shown that PMA induces an intracellular accumulation of antibody-ErbB2 complexes in a perinuclear compartment called the pericentrion [4] . Although we were not able to directly reproduce this localization, our results confirm that PKC activation causes internalization of antibody-ErbB2 complexes, and support that it causes sorting to a specialized compartment. Incubation with 17-AAG and PMA in combination caused an efficient internalization. As upon treatment with 17-AAG alone, Herceptin localized to both EEA1 and LAMP1 positive compartments. The size of each compartment was, however, clearly increased (Fig. 3) .
To determine the intracellular localization of ErbB2 itself in more detail, we initially used immunolabeling combined with confocal laser scanning microscopy ( Supplementary Fig. 1) . In control cells, ErbB2 staining was restricted to the plasma membrane. It should be noted that the cells were not incubated with CHX and downregulation can thus not be directly compared with the flow or immunoblotting data shown above. Still, in 17-AAG treated cells, the plasma membrane staining for ErbB2 was clearly reduced, while intracellular staining was increased localizing to EEA1 and LAMP1 positive compartments. This confirms previous studies showing that Hsp90 inhibition induces ErbB2 internalization and targets it for lysosomal degradation via the classical degradative pathway [28, 36] . The effect of PMA was less obvious, but compared to the control the intracellular labeling was increased, with partial colocalization with EEA1, but no apparent colocalization with LAMP1. The PMA + 17-AAG combination did, however, strongly reduce the plasma membrane staining and ErbB2 was instead localized to large vesicular compartments which were partially positive for EEA1 and LAMP1.
Since the effect of PMA was difficult to judge, we used immuno-EM to compare PMA-and 17-AAG-induced trafficking of ErbB2 in detail. In control cells, ErbB2 was concentrated at the plasma membrane, with only highly limited amounts in early endosome like compartments (Fig. 4A) , MVBs and the Golgi (data not shown). In line with previous studies, incubation with 17-AAG decreased the labeling for ErbB2 at the plasma membrane (data not shown) and strongly increased the labeling on internal vesicles of MVBs (Fig. 4B) , supporting trafficking to late endosomes and lysosomes for degradation. In cells treated with PMA, the plasma membrane labeling for ErbB2 remained strong. However, compared to control cells, the labeling also appeared more frequently in empty vesicular compartments which morphologically resemble enlarged early endosomes (Fig. 4C) . These probably correspond to the EEA1 positive compartments observed by confocal microscopy (see Fig. 3A ). Importantly, we also observed increased labeling for ErbB2 in what on micrographs appeared as small vesicles (Fig. 4D ) and tubular elements (Fig. 4E-F) . Since micrographs only show two dimensions within ultrathin sections, the labeling indicates localization of ErbB2 to what in three dimensions probably represent complex tubulovesicular and/or cisternal structures. The morphology is similar to a previously identified ERC [37] , and this supports that PKC activation causes sequestration of ErbB2 in a specialized recycling compartment. Quantification of the intracellular labeling verified the differences (Table 1) . While more than 40% of the labeling in 17-AAG treated cells localized to MVBs, almost 50% localized to clusters of vesicular and tubular structures in PMA treated cells. Under each condition about 1/3 of the labeling was classified as not characterized. This represents gold particles on single small vesicular structures not associated with clusters of vesicles or tubules, and labeling on areas with no clearly identified morphology. In cells incubated with the PMA + 17-AAG combination, as much as 70% of the labeling was concentrated in MVBs. These MVBs (Supplementary Fig. 2 ) were often found in groups and tended to be larger and more irregularly shaped compared to MVBs in control cells and cells exposed to 17-AAG only. Likewise the internal vesicles of the MVBs were more irregular in size and shape. 
PKC-mediated downregulation is clathrin-independent
ErbB2 does not bind to AP-2 and is considered to be internalization resistant [6] . Despite this, GA-mediated inhibition of Hsp90 induces clathrin-dependent internalization of ErbB2 [36] . Since the combination of PMA and 17-AAG had additive effect, which could suggest different mechanisms for ErbB2 internalization, we investigated to what extent clathrin-mediated endocytosis is involved. For this we used a PAE cell line (PAE.ErbB2) stably transfected with human ErbB2 as the only ErbB family member. This cell line was chosen since our previous studies show that we get a very efficient knock down of clathrin heavy chain (CHC) in PAE cells [12] . As shown in Fig. 5, 17 -AAGinduced downregulation of ErbB2 was efficiently inhibited while the downregulation of ErbB2 after PMA treatment was not influenced. This confirms that internalization of ErbB2 upon Hsp90 inhibition is clathrin-dependent, and importantly, it shows that PKC-mediated internalization occurs in a clathrin-independent manner. When PMA and 17-AAG were combined we observed no effect of CHC knockdown at early time points, indicating that PKC activation is sufficient to drive an efficient clathrin-independent internalization of ErbB2. After prolonged treatment, however, the internalization was clearly reduced in the clathrin knockdown samples. This suggests that when PKC activity is reduced due to the PMA-induced degradation (see Fig. 1B ), 17-AAGinduced clathrin-mediated endocytosis is the driving force.
PKC-mediated internalization is inhibited by cholesterol depletion
To further investigate PKC-mediated ErbB2 internalization, cells SK-BR-3 cells, treated as indicated for 4 h at 37°C, were prepared for immuno-EM. Sections were labeled using an antibody to the extracellular part of ErbB2 (TAB250), and the percentage distribution of gold particles localized to the indicated compartments was quantified. The results show the mean ± SD from three parallel labeling experiments.
were pre-incubated with methyl-β-cyclodextrin (MβCD) to deplete cholesterol before incubation with PMA. Flow cytometry showed that MβCD treatment in itself induced a slight reduction in the plasma membrane level of ErbB2, but importantly, there was no additional downregulation of ErbB2 upon PKC activation (Fig. 6 ). This demonstrates that PMA-induced internalization of ErbB2 is sensitive to cholesterol depletion. Cholesterol depletion may affect several endocytic pathways. It has been shown to mildly inhibit EGFR endocytosis [24, 45] , and incubation with MβCD may perturb the formation of clathrin coated pits [39] . However, as we find that PMA-induced ErbB2 internalization is clathrin-independent, we can exclude such side effects. The cholesterol dependence may indicate a role for lipid rafts, but the exact mechanisms involved in the internalization and a possible dependency of caveolin and/or other raft components, remains to be investigated.
3.6. Both PMA and 17-AAG decrease phosphorylation of ErbB2, but only 17-AAG induces ubiquitination
Phosphorylation and ubiquitination are important regulators of the stability and trafficking of, as well as signaling from, members of the ErbB family. It is well established that Hsp90 inhibitors like GA and 17-AAG induce ubiquitination of ErbB2 [10, 53, 55] and it has been shown that incubation with GA can reduce ErbB2 tyrosine phosphorylation [38] . Furthermore, while PKC activation induces threonine phosphorylation of ErbB2, it can inhibit the ErbB2 kinase activity and reduce the constitutive ErbB2 tyrosine phosphorylation [8, 34] . However, whether PKCs have effect on ErbB2 ubiquitination has, to our knowledge, not been investigated. This is important to look into, as we have previously shown that ubiquitination can serve as endocytosis signal for ErbB2 [51] . Immunoprecipitation of ErbB2 upon incubation with 17-AAG or PMA confirmed the effects on ErbB2 tyrosine phosphorylation (Fig. 7) . PMA reduced the tyrosine phosphorylation to a similar extend as did 17-AAG, but importantly, contrary to 17-AAG, PMA induced no measurable ErbB2 ubiquitination. Surprisingly, we found that Ro 31-8220 alone caused an increase in ErbB2 tyrosine phosphorylation (Fig. 7A  and B ). This effect was weakened by combinatorial treatment of Ro 31-8220 and PMA, while combinatorial treatment of Ro 31-8220 and 17-AAG showed the same effect as 17-AAG treatment alone. The reason for this is unclear, but it has been shown that PKC-mediated threonine phosphorylation of EGFR shifts the monomeric versus dimeric state of EGFR towards monomers [25] . It can thus be speculated that a basal PKC activity contributes to keeping ErbB2 as monomers and that Ro 31-8220 favors ErbB2 dimerization and activation.
As mentioned, ubiquitination was mainly driven by 17-AAG. While a combinatorial treatment with 17-AAG and PMA slightly increased the level of ubiquitination, 17-AAG and Ro 31-8220 in combination moderately decreased ubiquitination ( Fig. 7A and C) . All other treatments showed no measurable ubiquitination. How PKCs can affect 17-AAGinduced ErbB2 ubiquitination when PMA or Ro 31-8220 alone has no effect, is unclear. However, as for phosphorylation, it can be speculated that it has to do with the monomeric versus dimeric state of ErbB2. Importantly, ubiquitination explains why we observe a clear degradation of ErbB2 whenever 17-AAG is present. Why the reduced ubiquitination after combinatorial treatment with 17-AAG and Ro 31-8220 did not have an effect on ErbB2 internalization and degradation is unclear, but it indicates that the concentration of 17-AAG used induces an ErbB2 ubiquitination sufficient for inducing ErbB2 internalization and degradation. The observed increased degradation when 17-AAG and PMA were combined do on the other hand support that increased ubiquitination causes increased lysosomal sorting of ErbB2, and importantly, it shows that the degradative sorting signal induced by 17-AAG is superior to the stabilizing signal induced by PMA.
3.7. Ro 31-8220 and PMA increase 17-AAG induced Hsp70 recruitment
As described in the introduction, the exact role of Hsp90 in ErbB2 stabilization and as an inhibitor of ErbB2 internalization is still unclear. Hsp90 has been reported to retain ErbB2 at the plasma membrane through interaction with raft localized proteins like flotillins and members of the ERM protein family [2, 38] . Furthermore, Hsp90 inhibitors are known to reduce the Hsp90-ErbB2 interaction at the same time as they increase recruitment of Hsp70 and ubiquitin ligases like CHIP and/or CUL5 (reviewed in [7] ). Altogether, this could indicate that Hsp90 has to dissociate from ErbB2 before ErbB2 can be internalized. We therefore analyzed the amount of Hsp90 and Hsp70 which under different conditions co-immunoprecipitated with ErbB2 (Fig. 8) . As expected, 17-AAG mildly increased the recruitment of Hsp70, while Hsp90 interaction was clearly decreased. Hsp70 recruitment was even further increased when PMA or Ro 31-8220 were present along with 17-AAG, while the negative effect on Hsp90 interaction was partly counteracted by PMA, as well as Ro 31-8220. However, most importantly in this respect, neither PKC activation, nor PKC inhibition alone had any effect on the interaction between ErbB2 and Hsp90 or Hsp70.
Conclusions
Our data confirms that the otherwise endocytosis resistant ErbB2 can be internalized both upon Hsp90 inhibition and upon activation of PKCs, and that while Hsp90 inhibitors induce ErbB2 degradation, PKC activation induces stabilization. The different fates are most likely explained by different receptor modifications leading to internalization by different pathways, followed by differences in endosomal sorting. The 17-AAG data supports the notion that ubiquitination functions as a signal for clathrin-mediated internalization and ESCRT-mediated sorting of ErbB2 to late endosomes and lysosomes for degradation. The exact mechanisms involved in PMA-induced internalization are less clear. Our data shows that the internalization is clathrin-independent and sensitive to cholesterol depletion. However, as several clathrin-independent pathways exist, and most, but not all, to varying degrees are cholesterol sensitive (for recent reviews see [32, 43] ), the exact pathway remains to be identified. The cholesterol dependence and the previous identification of ErbB2 interaction with proteins like flotillins and ERMs can, however, indicate a role of lipid rafts in PMA-induced internalization. Another important regulator of internalization is dynamin. While clathrin-mediated endocytosis is dynamin-dependent both dynamin-dependent and -independent clathrin-independent pathways exist. The study by Bailey et al. indicated a role of Arf6 in PMA-induced Fig. 7 . 17-AAG but not PMA induce ubiquitination of ErbB2. SK-BR-3 cells, preincubated for 15 min with or without Ro 31-8220 (1 µM), were further incubated for 60 min with or without 17-AAG (3 µM) and/or PMA (100 nM). Cell lysates were subjected to immunoprecipitation under denaturing conditions using magnetic beads coated with an anti-ErbB2 (PAD:Z4881) specific antibody. Non-coated beads were used as control (-Ab). The immunoprecipitated proteins were immunoblotted using antibodies to ubiquitin (Ub). The membrane was stripped and blotted for phosphorylated tyrosine (pY), stripped again and blotted for ErbB2 (PAD:Z4881). One representative experiment out of three is shown. (B-C) Net luminescence of the bands corresponding to phosphorylated tyrosine (B) and ubiquitin (C) were quantified and normalized to immunoprecipitated ErbB2. Normalized values were plotted as ratios of control (untreated) (B) or 17-AAG (C). Data shown as mean ± SD and is representative of three independent experiments. n.s. non-significant, * p < 0.05, ** p < 0.01. *** p < 0.001.
ErbB2 trafficking [4] , and as Arf6-associated internalization has been shown to be cholesterol-dependent, but dynamin-independent [32] , it will be important to include dynamin-dependence in follow-up studies.
Our results support the notion that an important effect of Hsp90 inhibitors is to recruit Hsp70 and ubiquitin ligases, and that ubiquitination serves as a signal for clathrin-mediated internalization and lysosomal sorting of ErbB2. Since the ErbB2-Hsp90 complex interacts with raft localized proteins, it is also likely that Hsp90 inhibitors have a dual function and serve to release ErbB2 from rafts. However, most importantly, our results from PMA-induced PKC activation show that Hsp90 does not have to dissociate for ErbB2 to be internalized. Since we find that PMA-induced internalization of ErbB2 is clathrin-independent it is possible that ErbB2 and Hsp90 remain in complex with raft components upon internalization, and that this may contribute to the alternative endosomal sorting of ErbB2. The role of rafts and the interaction between ErbB2 and raft components will thus be important follow-ups to this study. It will be especially important to study whether flotillins and ERM proteins are internalized along with ErbB2 upon PKC activation.
The morphology of the pericentrion has to our knowledge not been described previously. Bailey et al. suggest that the compartment serves as a hub for ErbB2-mediated signaling. For this to occur, the C-terminal part of ErbB2 has to be exposed into the cytosol. Our immuno-EM data indicate that ErbB2 is internalized to enlarged, empty, early endosome like compartments and further sorted to a tubulovesicular or cisternal compartment which shows morphological resemblance with previously described ERCs. Contrary to the localization of ErbB2 to inner vesicles of MVBs, which is seen upon incubation with 17-AAG, the C-terminal part of ErbB2 will in these compartments be exposed to the cytosol and signal transduction may occur. The sustained downregulation further indicates that ErbB2 is retained in this compartment. Why it is not recycled is unclear, but for the EGFR it has been shown that the retention depends on PKC-mediated Thr-654 phosphorylation. We did not study PMA-induced Thr phosphorylation, but since PKCs can induce phosphorylation at Thr-686 in ErbB2, it is likely that ErbB2 is retained by mechanisms similar to those retaining EGFR.
